Health & Medicine

STAT+: A rare disease drug was approvable, then it wasn't. Inside a surprise rejection by the FDA

21 sec read39 views0 listens

The FDA unexpectedly rejected a rare blood cancer drug developed by Atara Biotherapeutics and Pierre Fabre Pharmaceuticals after internal reviewers had initially recommended approval; this reversal highlights potential shifts under new leadership at the FDA, emphasizing uncertainty for content creators covering pharmaceutical approvals.

Read the full article at STAT News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Tech & Gadgets11 hours ago25 sec read

How Toronto is using Clariti's AI to speed up building permit approvals

Toronto has launched a one-year pilot program with Clariti's CivCheck AI software to expedite the city's building permit approval process. This initiative aims to reduce delays caused by incomplete applications, which can add significant costs for de...

Ali Nemati

Biotech & Pharma14 hours ago28 sec read

CAR T-Cell Therapy Puts Severe Rheumatoid Arthritis Into Remission in First Clinical Trial

A Phase 1 clinical trial at Charité—Universitätsmedizin Berlin has shown that CAR T-cell therapy significantly reduced disease activity in six patients with severe, treatment-refractory rheumatoid arthritis (RA), with three achieving sustained remiss...

Ali Nemati

Biotech & Pharma19 hours ago26 sec read

STAT+: Pharmalittle: We're reading about an AstraZeneca trial failure, a 'monstrous' conflict of interest, and more

AstraZeneca's heart disease trial for its experimental drug failed, showing no additional benefits for patients already on stabilizer drugs. This setback highlights challenges in a competitive market and underscores the difficulty of improving outcom...

Ali Nemati